Fresenius SE KGaA (XTER:FRE) Research & Development: €656 Mil (TTM As of Mar. 2026)


XTER:FRE Fresenius SE & Co KGaA XTER:FRE
67 GF Score
Price €40.07
GF Value €36.55
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Fresenius SE KGaA Research & Development?

Fresenius SE KGaA XTER:FRE +0.43% 67 Research & Development is €656 Mil as of Mar. 2026. GuruFocus rates XTER:FRE with a GF Score™ of 67/100 and a GF Value™ of €36.55 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Fresenius SE KGaA's Research & Development for the three months ended in Mar. 2026 was €163 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €656 Mil.

Fresenius SE KGaA  (XTER:FRE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Fresenius SE KGaA Research & Development Related Terms

Fresenius SE KGaA Research & Development Historical Data

* Premium members only.

The historical data trend for Fresenius SE KGaA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fresenius SE KGaA Research & Development Chart

Fresenius SE KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 805.00 639.00 661.00 641.00 633.00

Fresenius SE KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 140.00 164.00 159.00 170.00 163.00
XTER:FRE
67GF Score
Fresenius SE & Co KGaA XTER:FRE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fresenius SE KGaA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €656 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €656 Mil mean?
Fresenius SE KGaA (XTER:FRE) has a Research & Development of €656 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Fresenius SE KGaA and its competitors.
Is Fresenius SE KGaA's Research & Development too high?
Fresenius SE KGaA's current Research & Development is €656 Mil. Overall, Fresenius SE KGaA has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Research & Development compare to HCA and THC?
Fresenius SE KGaA's Research & Development of €656 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Fresenius SE KGaA and its competitors. Fresenius SE KGaA's current Research & Development is €656 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XTER:FRE) is currently considered Fairly Valued. The stock's GF Value™ is €36.55, compared to a current price of €40.07 — trading 9.6% above its estimated fair value. The current Research & Development is €656 Mil. Fresenius SE KGaA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Fresenius SE KGaA (XTER:FRE), the current Research & Development is €656 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fresenius SE KGaA (XTER:FRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued. The current stock price of €40.07 is trading 9.6% above its estimated GF Value™ of €36.55. GuruFocus considers Fresenius SE KGaA to be Fairly Valued.

Key valuation signals for XTER:FRE:

  • Research & Development: €656 Mil
  • GF Value™: €36.55 vs. price of €40.07 (9.6% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the XTER:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fresenius SE KGaA Business Description

Address Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
67GF Score

Get the complete analysis for XTER:FRE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.07
Price
€36.55
GF Value